InventisBio opens Phase 1 liver-function PK study of D-2570 in China
The trial will measure how hepatic impairment alters D-2570's pharmacokinetics, a standard bridging step that this indication has not required for InventisBio's asset before.
Executive Summary
- InventisBio has opened a Phase 1 pharmacokinetic study testing how impaired liver function changes the way D-2570 is absorbed, distributed, and cleared, compared with participants who have normal hepatic function.
- The design is a standard bridging study, not an efficacy trial: it measures drug exposure and clearance rather than clinical benefit, and it carries no comparator drug arm.
- D-2570 sits among a wide field of small-molecule programs running similar hepatic-impairment pharmacokinetic studies for unrelated targets, none of which compete on mechanism with D-2570.
- InventisBio brings a track record of completing the large majority of its trials, which supports execution confidence on a study of this size and duration.
The catalyst
InventisBio Co., Ltd registered NCT07715149, a Phase 1 pharmacokinetic study titled "A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function." The trial started enrolling on July 14, 2026, and targets 24 participants across three arms at a single site in China. It is open-label and non-randomized, with a primary completion date of October 31, 2026, and full completion set for November 30, 2026. NCT07715149A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic FunctionNCT07715149
What the trial measures
The registered primary endpoints are pharmacokinetic parameters, maximum plasma concentration (Cmax), time to maximum concentration (Tmax), half-life, area under the concentration curve (AUC), apparent clearance (CL/F), and apparent volume of distribution (Vz/F), each measured through 192 hours after the last dose. Incidence of adverse events is tracked as a secondary endpoint through Day 9. The design compares participants with hepatic impairment to those with normal hepatic function, the standard approach regulators use to set dosing guidance for patients whose liver disease could slow drug clearance and raise exposure. NCT07715149A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic FunctionNCT07715149
Where it sits competitively
D-2570's target and mechanism of action are not established in available records, so no claim of novelty or isolation attaches to this program. The competitive field surfaced for this indication consists almost entirely of small-molecule programs running comparable hepatic-impairment pharmacokinetic studies for unrelated targets, including Pfizer's PF-07328948, Otsuka's Repinatrabit, Insmed's Treprostinil Palmitil, and Chia Tai Tianqing's Unecritinib, none of which shares D-2570's mechanism. This is a modality-precedent field: dose-characterization studies of this kind are common practice across the industry rather than a differentiated clinical test, and D-2570's positioning here is procedural, not competitive.
Sponsor track record
InventisBio has completed 17 of 18 prior trials with one terminated, a 94% completion rate across its global portfolio. The company currently runs 8 recruiting trials and 5 active-not-recruiting trials alongside this study, giving it an established base for operational execution on a small, single-site bridging trial. No FDA approval history or regulatory designation is on record for D-2570 in this indication.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.